19th Expert Committee on the Selection and Use of Essential Medicines: Medicines for children
Applications for paediatric medicines
- Abacavir (New formulation) -- Children
- Abacavir + lamivudine (Addition) -- Children
- Amphotericin (To be moved to core list) -- Adults and Children
- Anaesthetics (Review) -- Children
- Antiarrhythmics (Review) -- Children
- Antiretrovirals (Formulations to be considered for possible deletion) -- Adults and Children
- Artesunate + mefloquine (Addition) -- Adults and Children
- Azithromycin (Addition) -- Adults and Children
- Benznidazole (New formulation) -- Children
- Benzoyl peroxide (Review) -- Adults and Children
- Chlorhexidine (New formulation) -- Children
- Chlorpromazine and haloperidol (Deletion) -- Children only
- Colloids (Review) -- Children
- Dexamethasone (New indication) -- Children
- Ear, nose and throat (Review) -- Adults and Children
- Efavirenz (New formulation) -- Children
- Flucytosine (To be moved to core list) -- Adults and Children
- Fluoxetine (Change to age restriction/Deletion from EMLc) -- Adults and Children
- Fomepizole (Addition) -- Adults and Children
- Histamine-1 receptor antagonists (Review) -- Adults and Children
- Human normal immunoglobulin (Additional dosage) -- Adults and Children
- Hydromorphone (Addition) -- Children
- Imatinib (Addition) -- Adults and Children
- Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim (Addition) -- Adults and Children
- Ketotifen (Addition) -- Adults and Children
- Lamivudine + nevirapine + zidovudine (New formulation) -- Children
- Lamivudine + stavudine (New formulation) -- Children
- Lamivudine + zidovudine (New formulation) -- Children
- Montelukast (Addition) -- Children
- Morphine (New formulation) -- Children
- Nevirapine (New formulation) -- Children
- Nifurtimox + eflornithine (Addition) -- Children
- Nifurtimox + eflornithine (Review) -- Adults and Children
- Ofloxacin (Addition) -- Adults and Children
- Oseltamivir (Deletion) -- Adults and Children
- Oxycodone (Addition) -- Children
- Palliative care (New section) -- Children
- Second-line antituberculosis medicines (Review) -- Children
- Statins (Review) -- Children
- Streptomycin (To be moved to complementary list) -- Children
- Whole blood and red blood cells (Addition) -- Adults and Children
Contact: emlsecretariat@who.int
Medicine Access and Rational Use (MAR)
20 Avenue Appia
CH-1211 Geneva 27